GSK signed a deal to access Chai Discovery’s protein-folding and design models. GSK evaluated the models across diverse targets. The models generated designs to GSK targets without target-specific training. GSK’s wet-lab tests found binders to all tested targets. Chai’s earlier model achieved a 16% hit rate in fully de novo antibody design. Chai’s latest model, Chai-3, targets high success rates and binding affinities. Chai has partnerships with Bristol Myers Squibb, Eli Lilly, Novartis and Pfizer. Chai raised a $400 million Series C round this year. GSK also signed an $110 million deal with Relation for AI-driven data generation.
What changed
GSK had not adopted Chai Discovery’s protein-folding and design models.
What it unlocks
Using Chai’s models to generate antibody designs without target-specific training.
- 16% hit rate in de novo antibody design
- $400M Series C
- $110M GSK deal with Relation
What you need to act on it
- wet-lab validation by GSK
- access to Chai’s platform
Sources